Targeted inhibition of RECQ1 expression or pharmacological inhibition of RECQ1 enzymatic activity could potentially enhance therapeutic action of anticancer drugs in p53-deficient tumor cells that are much more reliant than normal cells on pathways that resolve replication stress. Here, RECQL is linked to neoplasm.